Abstracts

A JAK1 INHIBITOR SUPPRESSES HIV-1-DRIVEN ABERRANT HOST GENE TRANSCRIPTION

More than 50% of the latent reservoir are maintained through clonal expansion. While ART effectively blocks new rounds of infection, HIV-1 promoter remains intact, drives HIV-1 expression and aberrant cancer-related gene expression, and contributes to HIV-1 integration site-related clonal expansion. New therapeutic approaches targeting the clonal expansion of HIV-1-infected cells is required to reduce the size of…

BRENTUXIMAB VEDOTIN REDUCES CD30 EXPRESSION AND GUT HIV DNA LEVELS IN HUMANIZED MICE

CD30 is preferentially expressed in HIV-infected and viral transcriptionally active CD4 T cells from viremic and ART suppressed individuals. We observed treatment with anti-CD30 antibody drug conjugate, brentuximab vedotin (BV), leads to reduced cell-associated HIV DNA in vitro and transient decreases in cell-associated HIV RNA in vivo. The impact of anti-CD30 therapy on tissue measures…

PGT121 AND VESATOLIMOD IN CHRONICALLY TREATED SHIV-INFECTED RHESUS MONKEYS

We have previously reported that administration of the broadly neutralizing antibody PGT121 with the TLR7 agonist vesatolimod (VES) delayed or prevented viral rebound in SHIV-infected rhesus monkeys following ART discontinuation in animals that initiated ART early during acute infection.  However, the efficacy of bNAbs has not previously been evaluated in the more clinically relevant model…

CCR5Δ32 SCT-INDUCED HIV REMISSION: TRACES OF HIV DNA BUT FADING IMMUNE REACTIVITY

To date only 3 patients have achieved long-term HIV-remission after analytic therapy interruption (ATI). Here we provide an update of the Duesseldorf patient (IciStem#19). This HIV-infected male patient (50y, heterozygous CCR5∆32 allele) received unmodified stem-cell transplantation (SCT) from a 10/10 matched CCR5Δ32/Δ32 donor in Feb/13 for acute myeloid leukemia. At time of SCT complete western…

VIRAL RESERVOIR DISRUPTION WITH PANOBINOSTAT AND IFN-Α: FIRST RESULTS

Reactivation of viral transcription can sensitize viral reservoir cells to immune-mediated killing which may reduce long-term persistence of virally-infected CD4+ T cells in ART-treated individuals. The ACTIVATE study is an ongoing, prospective, randomized, dose-escalation clinical trial in which the histone deacetylase inhibitor (HDACi) panobinostat is administered as a latency-reversing agent in combination with pegylated IFN-α2a…